Test Price
2,800 AED✅ Home Collection Available
KCNE3 Gene Brugada Syndrome Type 6 Genetic Test – 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
This KCNE3 gene sequencing test employs Next Generation Sequencing (NGS) with Sanger confirmation to detect pathogenic variants linked to Brugada syndrome type 6, a cardiac ion channelopathy associated with sudden cardiac death. The assay achieves 99.9% diagnostic sensitivity for single nucleotide variants and small insertions/deletions, with full coverage of coding exons and splice junctions. Turnaround time is 3 to 4 weeks from sample receipt. Direct insurance verification is available via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The KCNE3 genetic test screens for mutations in the KCNE3 gene that predispose to Brugada syndrome type 6, a potentially fatal channelopathy that increases the risk of sudden cardiac death in young adults. Comprehensive molecular analysis of the entire coding region and splice sites enables accurate risk stratification for patients and their at-risk relatives. Results are interpreted according to current ACMG guidelines and integrated with clinical ECG findings and family history for definitive diagnosis.
| Feature | Our Test (Precision / Method / Speed) | Closest Alternative |
|---|---|---|
| Technology | Next Generation Sequencing (NGS) + Sanger confirmation, full gene coverage | Single‑gene Sanger sequencing of selected exons only |
| Sensitivity | 99.9% for single nucleotide variants & small indels; large deletion/duplication analysis included | ~95% for point mutations; misses copy number variants |
| Turnaround Time | 3 to 4 weeks | 4 to 6 weeks |
Physician Insight & Safety Protocols
Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403): “Genetic testing for Brugada syndrome provides families with critical risk information, yet it is not a standalone diagnosis. A negative result does not exclude the condition if clinical suspicion is high, and results must always be interpreted alongside a 12-lead ECG and specialist cardiology evaluation. Patient safety and informed decision-making are our foremost priorities.”
Advisory Notice – Medication Safety
Patients currently prescribed antiarrhythmic therapy must not discontinue or alter their medication without explicit instruction from their treating cardiologist. Abrupt withdrawal of such drugs may provoke life‑threatening arrhythmias. Always consult your physician before making any changes to prescribed treatment.
Exclusion Criteria & Emergency Red Flags
- Exclusion – Transfusion Interference: Not suitable for patients who have received an allogeneic blood transfusion within 4 weeks or prior allogeneic stem cell transplant due to risk of donor DNA interference.
- Exclusion – Consent: Individuals unable to provide informed consent. For minors, parental/legal guardian consent and a genetic counselling session are required in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags – proceed to ER immediately if: Unexplained syncope (fainting), nocturnal agonal respiration, palpitations with dizziness, or family history of sudden cardiac death under 45 years.
Patient FAQ & Clinical Guidance
1. What exactly does the KCNE3 NGS test detect and why is it important?
Answer: The KCNE3 NGS test comprehensively screens for mutations in the KCNE3 gene that cause Brugada syndrome type 6, a cardiac ion channelopathy that predisposes to sudden cardiac death. It analyzes the entire coding region and splice sites of KCNE3, identifying pathogenic variants that disrupt cardiac ion channels and lead to a high-risk ECG pattern. This genetic information enables targeted surveillance, lifestyle modifications, and treatment plans for affected individuals and at-risk relatives. Results are interpreted according to current ACMG guidelines.
2. How do I prepare for the test and what does the process involve?
Answer: Preparation includes a mandatory genetic counselling session to draw a pedigree chart and review your family history of sudden cardiac events. Our VIP mobile phlebotomist will collect a blood sample at your home between 8 AM and 11 PM, using hospital‑grade cold‑chain transport. No special fasting or medication changes are required unless directed by your physician. The sample is processed under ISO 9001:2015 certified conditions, and results are reported within 3 to 4 weeks.
3. Does my insurance cover the cost of this genetic test?
Answer: Coverage depends on your policy. We verify insurance directly via WhatsApp and provide a detailed invoice for reimbursement claims. Send a copy of your insurance card to +971 54 548 8731, and we will check coverage before the test is performed. If full coverage is not available, flexible payment options and a comprehensive invoice for insurance reimbursement are offered. All genetic data is protected under UAE data privacy laws.
4. What is the sample type required for this test?
Answer: The test requires a standard peripheral whole blood sample (5–10 mL) collected in an EDTA tube. This specimen is suitable for DNA extraction and NGS analysis. The sample can be collected at home via our VIP mobile phlebotomy service or at any DNA Labs UAE collection center.
5. How are results interpreted and who explains them to me?
Answer: Results are interpreted by our Consultant Medical Geneticist using ACMG variant classification criteria. A post-test genetic counselling session is included to explain the findings, discuss implications for family members, and coordinate with your cardiologist for further management if needed.
UAE Regulatory & Data Privacy Adherence
Data Protection Compliance: This laboratory service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed solely for diagnostic purposes. Consent for testing, including genetic counselling requirements, follows Federal Decree-Law No. 4 of 2016 on Medical Liability. DHA Facility License No: 1143. ISO 9001:2015 Certified. Direct billing support: +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | KCNE3 Gene Brugada Syndrome Type 6 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) – EDTA tube |
| Methodology Used | Next Generation Sequencing (NGS) + Sanger Confirmation |
| ICD-10-CM Code | I49.8 |
| LOINC Code | 55233-1 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians